Convert unstructured KOL interaction notes into structured intelligence across scientific themes, competitive signals, advocacy gaps, and emerging unmet needs. Aggregate field signal across 50+ MSLs. Surface decision-ready insights for Medical Affairs Leadership.
Paste an MSL field note or use sample data. AI extracts scientific themes, competitive signals, advocacy gaps, unmet needs, and KOL sentiment — in seconds.
Paste a free-text field note from your last KOL interaction, or click "Load Sample" above to populate with a realistic NSCLC engagement example.
Click "Load Sample Note" above or process your own note to see structured AI extraction across 5 intelligence dimensions.
Roll up tagged notes across the MSL team. Identify recurring themes, escalating signals, and emerging patterns invisible at the individual-note level.
Darker cells = higher mention frequency. Identifies where strategic themes are gaining traction (or being ignored).
| KOL Segment | Efficacy | Safety/AE | Combo Strategy | Biomarker | Competitor | Advocacy |
|---|---|---|---|---|---|---|
| Tier 1 Academic (n=18) | 82 | 64 | 94 | 71 | 88 | 102 |
| Tier 2 Academic (n=32) | 68 | 52 | 72 | 42 | 68 | 61 |
| Community Oncology (n=64) | 82 | 88 | 35 | 22 | 48 | 28 |
| Pathway Influencers (n=12) | 88 | 68 | 60 | 70 | 80 | 90 |
| Emerging KOLs (n=22) | 42 | 35 | 55 | 60 | 42 | 34 |
Per-KOL profile aggregating all MSL interactions: scientific interests, advocacy disposition, competitive concerns, recommended next actions.
| KOL | Status | Recommended Action | Priority | Owner |
|---|---|---|---|---|
| Dr. Reck | Sentiment decline | Schedule 1:1 with Chief Medical Officer to address OS extrapolation skepticism with new RWE data | High | Sarah Chen (MSL Lead EU) |
| Dr. Herbst | Advisory ready | Send advisory board invitation + biomarker preliminary data for Q4 meeting | High | James Rodriguez |
| Dr. Mok | APAC opportunity | Connect with APAC commercial lead — Co-PI interest signals expansion potential | High | Priya Sharma |
| Dr. Peters | Engagement+ | Provide elderly subgroup safety pooled analysis. Steering committee Q1 update | Med | Sarah Chen |
| Dr. Drilon | Publication track | Manuscript co-authorship invitation for biomarker analysis (JCO target) | Med | Marcus Webb |
| Dr. Cappuzzo | Speaker active | Confirm Italian regional speaker tour Q1 — 6 cities, payer-focused content | Standard | James Rodriguez |
Track how scientific themes and competitive signals evolve quarter-over-quarter. Detect emerging concerns before they become major issues.
| Emerging Signal | First Detected | Volume | Trend |
|---|---|---|---|
| Elderly pneumonitis rate concern | Sep 05 | 11 | ▲ Rising |
| Biomarker PD-L1 + TIGIT correlation | Aug 28 | 14 | ▲ Rising |
| 1L combination expansion demand | Jul 02 | 24 | ▲ Strong |
| Competitor TIGIT pneumonitis | Aug 14 | 18 | ▲ Rising |
| Domvanalimab enrollment delay | Sep 10 | 5 | → Stable |
| Subcutaneous formulation interest | Sep 22 | 4 | ▲ New |
| Patient adherence improvement | Aug 18 | 7 | → Stable |
| Healthcare resource utilization | Sep 15 | 3 | ▲ New |
One-click executive briefing synthesizing all field intelligence into a board-ready report. Replaces weekly manual synthesis (avg 6 hours / week).
Q3 2026 field intelligence from 2,847 MSL interactions across 42 MSLs reveals four strategic priorities for leadership attention: (1) 1L combination demand sustained at high level among Tier 1 KOLs — strategic acceleration warranted; (2) Competitor TIGIT class-effect pneumonitis emerging as defensive opportunity; (3) Elderly safety subgroup concerns require pre-emptive communication; (4) Advisory board interest surge presents engagement capacity opportunity post-ASCO data.
Signal: 24 Tier 1 KOLs requested 1L combination data over the past 90 days — sustained across all geographies (US, EU, APAC).
Implication: Current 2L positioning leaves significant whitespace and competitive risk if Domvanalimab or Vibostolimab achieves 1L approval first.
Recommendation: Submit pre-IND meeting request to FDA for Phase 3 1L combination (ASC-301 + pembrolizumab vs SoC). Allocate 12 additional clinical sites Q1 2027. Estimated incremental NPV: $1.4-2.1B.
Signal: 18 MSL interactions cited competitor TIGIT Grade 3+ pneumonitis cases (Roche tiragolumab, Merck vibostolimab) — KOLs proactively raising class-effect concern.
Implication: Competitive vulnerability creates positioning opportunity if our safety profile holds favorably (ASC-301 G3+ pneumonitis 3% vs competitor 7-9%).
Recommendation: Develop comparative safety analysis (pooled trial data + RWE confirmation). Brief Tier 1 KOLs at upcoming WCLC. Update MSL talking points with comparative AE profile.
Signal: 11 MSL interactions raised concerns about elderly (>75y) pneumonitis rates after ASCO presentation of subgroup data showing 1.6× rate.
Implication: Without proactive communication, this could become a label restriction risk during FDA review.
Recommendation: Issue Dear Healthcare Provider letter with elderly-specific monitoring protocol. Update Medical Information response letters. Plan elderly subgroup symposium at ESMO 2027.
Signal: 8 Tier 1 KOLs offered to join advisory board post-ASCO. Current capacity 12 seats; current roster 11 — capacity gap.
Implication: Decline-by-default would damage relationships with high-value KOLs at peak engagement moment.
Recommendation: Expand advisory board to 16 seats. Create regional sub-boards (US, EU, APAC) for tier 1 KOL roles. Activate 3 candidates immediately, 2 in Q1 2027, 3 in Q2 2027.